Prosigna

Prosigna is a test for breast cancer developed by Veracyte to measure recurrence risk. It adds prognostic information to conventional risk factors such as pathological analysis of the patient tumor, and protein markers detected using immunohistochemistry. The product is intended for post-menopausal women with early-stage breast cancer.